Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Avicularin is a flavonoid glycoside that has been found in R. sachalinensis and has diverse biological activities.1,2,3,4,5 It inhibits fatty acid synthase (FASN) and aldose reductase (IC50s = 6.15 and 19.05 µM for the chicken liver and human enzymes, respectively).1,2 Avicularin scavenges DPPH and superoxide radicals, as well as inhibits copper-induced oxidation of LDL in cell-free assays (IC50s = 64.3, 6, and 3.8 µM, respectively).3 It inhibits LPS-induced increases in nitric oxide (NO) and prostaglandin E2 (PGE2; Item No. 14010) production in RAW 264.7 macrophages when used at concentrations ranging from 30 to 300 µM.4 Avicularin (100 µg/ml) inhibits the proliferation, migration, and invasion of, as well as induces apoptosis and cell cycle arrest at the G0/G1 phase in, Huh7 hepatocellular carcinoma cells.5
WARNING This product is not for human or veterinary use.
1. The lipogenesis pathway as a cancer target. J. Med. Chem. 54(16), 5615-5638 (2011).
2. Construction of an Indonesian herbal constituents database and its use in Random Forest modelling in a search for inhibitors of aldose reductase. Bioorg. Med. Chem. 20(3), 1251-1258 (2012).
3. Antioxidant activity of anthraquinones and flavonoids from flower of Reynoutria sachalinensis. Arch. Pharm. Res. 28(1), 22-27 (2005).
4. Avicularin inhibits lipopolysaccharide-
5. Avicularin ameliorates human hepatocellular carcinoma via the regulation of NF‑κB/COX‑2/PPAR‑γ activities. Mol. Med. Rep. 19(6), 5417-5423 (2019).